Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
Marc Davis | September 1, 2020 |

Buzz on the Bullboards: Stocks making headlines

It can be hard to know when to make a move when every day looks crazier than the last. Traders don’t not know what to expect coming in tomorrow’s news cycle … but you can bet the markets are going to be volatile day-to-day. This has bee...
Jonathon Brown | October 12, 2023 |

US between Scylla and Charybdis

I’m just going to come right out and say it: The United States is not equipped to deal with a pandemic. The nation of 327 million, despite having the number one economy in the world, and by far the most powerful military, is shockingly ill-prepared, not only ...
Richard (Rick) Mills | March 31, 2020 |

Updated PFS Expected to Show Improved Economics for Australia Gold Project

The reasons for the better scenario are discussed in a ROTH Capital Partners report. In a May 29 research note, ROTH Capital Partners analyst Jake Sekelsky reported that recent additional metallurgical test results from Vista Gold Corp.'s (VGZ:NYSE.MKT; VGZ...
Streetwise Reports | June 4, 2019 |

Novo Scores +1 Gram Per Meter at Egina

It's been eight months since I have delivered an update on Novo Resources Corp. (NVO:TSX.V; NSRPF:OTCQX) . While Novo has put out a fair number of press releases since then I have been waiting for some solid red meat. They have just put out red meat that should satis...
Streetwise Reports | August 26, 2019 |

Buzz on the Bullboards: New Rising Opportunities

There has been a lot of attention on the tech sector and the stocks working in that marketplace as of late. Despite market volatility, the tech-heavy Nasdaq has displayed much growth this year as it dug itself out of the COVID hole that had investors and the markets at large p...
Stockhouse Editorial | September 30, 2020 |

PCR Testing: XPhyto Disrupts a Blockbuster Business

It’s the technological evolution that could transform the US $84.4 billion Covid-19 diagnostics market. Vancouver-based life sciences company XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) expects its rapid Covid-19 test system to be approv...
Marc Davis | February 25, 2021 |

Analyst Stress Tests Sustainability of Occidental Petroleum's Common Dividend

The methods and findings of this analysis are presented in a Raymond James report. In a May 22 research note, Raymond James analyst Pavel Molchanov reported that Occidental Petroleum Corp.'s (OXY:NYSE) current "lofty" dividend yield could be the market sig...
Streetwise Reports | May 28, 2019 |

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. Immuno-pharmaceutical company AIM Imm...
Streetwise Reports | March 10, 2020 |

Buzz on the Bullboards: COVID-19 Testing Plays

There are many investing plays that are attractive to serious investors and small-cap opportunists in the current market, but coronavirus movements take the cake. We’ve noted that each sector has its share of positive opportunities for both long-term and sh...
Omri Wallach | May 6, 2020 |
1 2 3 4 5 6 7 8 9 10 ...